Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
COVID-19
SARS-CoV-2
Spike gene
bamlanivimab
convalescent plasma
immunocompromised
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
29
10
2021
received:
16
09
2021
accepted:
07
11
2021
pubmed:
11
11
2021
medline:
7
6
2022
entrez:
10
11
2021
Statut:
ppublish
Résumé
Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.
Identifiants
pubmed: 34755363
doi: 10.1002/jmv.27445
pmc: PMC8661643
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
bamlanivimab
45I6OFJ8QH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241-1245Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Elife. 2020 Oct 28;9:
pubmed: 33112236
Emerg Infect Dis. 2021 Oct;27(10):2725-2728
pubmed: 34352197
Clin Infect Dis. 2021 Dec 6;73(11):2144-2145
pubmed: 34009286
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Emerg Infect Dis. 2021 Oct;27(10):2728-2731
pubmed: 34314668
Vaccines (Basel). 2021 Aug 23;9(8):
pubmed: 34452062
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Viruses. 2021 Aug 19;13(8):
pubmed: 34452507
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
J Infect Dis. 2020 Sep 1;222(7):1103-1107
pubmed: 32702095
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
J Med Virol. 2022 Mar;94(3):1241-1245
pubmed: 34755363
Diagn Microbiol Infect Dis. 2022 May;103(1):115656
pubmed: 35231807
J Clin Microbiol. 2021 Jun 18;59(7):e0074121
pubmed: 33952596
J Infect. 2022 Feb;84(2):248-288
pubmed: 34437928
Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11
pubmed: 34171266